Jazz Pharmaceuticals price target raised to $151 from $145 at RBC Capital

RBC Capital analyst Gregory Renza raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $151 from $145 and keeps an Outperform rating on the shares. After the company hosted an investor call for recently approved Modeyso for the treatment of rare H3 K27M mutant gliomas, the firm has come away more bullish on the potential opportunity for the agent, the analyst tells investors in a research note. RBC is citing higher than expected pricing, a committed launch strategy from Jazz with 50 reps already in place, and a highly motivated patient and prescriber base.